MPM BioImpact’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

MPM BioImpact’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,003,406	Closed	-$38.6M	–	36
2023 Q2	$38.6M	Buy	1,003,406 +805,600	+407%	+$20.7M	7.76%	3
2023 Q1	$4.58M	Buy	197,806 +117,806	+147%	+$2.81M	1.19%	22
2022 Q4	$2.1M	Buy	+80,000	New	+$1.77M	0.54%	28

MPM BioImpact's KDNY Position: Q3 2023 in Review

MPM BioImpact sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 1,003,406 shares — an estimated $38.6M sold.

MPM BioImpact first reported a position in KDNY in Q4 2022 and held it in 3 quarters. The position peaked at $38.6M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

MPM BioImpact reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
MPM BioImpact sold 1,003,406 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $38.6M.
MPM BioImpact first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
MPM BioImpact's Chinook Therapeutics, Inc. Common Stock position peaked at $38.6M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on MPM BioImpact's 13F filing for Q3 2023, filed 14 Nov 2023.